Bodenheimer M M, Banka V S, Helfant R H
Am J Cardiol. 1980 Mar;45(3):674-84. doi: 10.1016/s0002-9149(80)80021-x.
Since its introduction, thallium-201 has become the agent of choice in the clinical assessment of relative myocardial perfusion. Extensive evaluation has shown that it is of particular value in the diagnosis of coronary heart disease in patients with baseline S-T segment abnormalities or an inadequate heart rate response resulting in an inconclusive exercise electrocardiographic response. In addition, thallium-201 imaging is of value in the patient with a suspected false positive stress test; however, the definite incidence of false negative studies in patients with coronary heart disease tempers complete reliance on this approach. In the patient with a diagnostic exercise electrocardiographic stress test, thallium-201 provides limited additional information. Moreover, current techniques of analysis do not permit assessment of the number of coronary arteries with obstructive lesions. In the setting of acute myocardial ischemia, the role of thallium-201 is less clear. In acute myocardial infarction, the significant incidence of false negative responses combined with a multiplicity of potential causes of resting defects including severe but chronic coronary disease or unstable angina limits its diagnostic value.
自引入以来，铊-201已成为相对心肌灌注临床评估中的首选药物。广泛评估表明，它在诊断基线S-T段异常或心率反应不足导致运动心电图反应不确定的冠心病患者中具有特殊价值。此外，铊-201显像对于疑似运动试验假阳性的患者有价值；然而，冠心病患者中假阴性研究的确切发生率限制了对这种方法的完全依赖。对于诊断性运动心电图应激试验的患者，铊-201提供的额外信息有限。此外，目前的分析技术无法评估有阻塞性病变的冠状动脉数量。在急性心肌缺血的情况下，铊-201的作用尚不清楚。在急性心肌梗死中，假阴性反应的高发生率以及包括严重但慢性冠心病或不稳定型心绞痛在内的静息缺损的多种潜在原因限制了其诊断价值。
